Similar results were observed in the repeat experiment.<h4>Conclusions</h4>In a mouse model of letrozole-resistant breast cancer with no ESR1 mutations, reduced levels of ERα, and overexpression of HER2, lasofoxifene alone or combined with palbociclib inhibited primary tumor growth more effectively than fulvestrant. Here, ERBB2 is linked to breast cancer.